Edgar Filing: CHIRON CORP - Form 4

CHIRON C Form 4	ORP							
February 22	2, 2006							
FORM	Λ4						PPROVAL	
	UNITED	OMB Number:	3235-0287					
Check t if no lor subject Section Form 4 Form 5 obligati- may cor <i>See</i> Inst 1(b).	nger to 16. or Filed pur ons ntinue.	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940						
(Print or Type	Responses)							
(I fint of Type	Responses)							
1. Name and Bartels Urs	Symbol		d Ticker or Trading	5. Relationship of Reporting Person(s) to Issuer				
(1 +)				(Check all applicable)				
(Last) 4560 HOR		of Earliest 7 /Day/Year) 2006	Iransaction	Director 10% Owner Officer (give title Other (specify below) V.P. & General Counsel				
	(Street)		nendment, D onth/Day/Yea	Date Original ar)	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
EMERYV	ILLE, CA 94608				Person	Aore than One R	eporting	
(City)	(State)	(Zip) Ta	ble I - Non-	Derivative Securities	Acquired, Disposed of	f, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)	4. Securities onAcquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or Amount (D) Pric	Securities H Beneficially (Owned (Following (Reported Transaction(s) (Instr. 3 and 4)	5. Ownership Form: Direct D) or Indirect I) Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder De	port on a senarate line	for each class of co	ourities have	ficially owned directly	v or indirectly			
Keminder: Ke	port on a separate line	tor each class of se	curities dene	information con required to res	y or indirectly. espond to the collect ntained in this form pond unless the form ently valid OMB con	are not m	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onof Derivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: CHIRON CORP - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year) (Instr. 8)			Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)					
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amoun or Number of Shares
Restricted Stock Units (1)	<u>(2)</u>	02/17/2006		A <u>(3)</u>		1,900		02/17/2007(4)	02/16/2010	Common Stock	1,900

Reporting Owners

Relationships							
Director	10% Owner	Officer	Other				
		V.P. & General Counsel					
Ursula B. Bartels by Naima Robinson as Attorney in Fact							
ng Person		Date					
	binson as	bbinson as Attorney	Director 10% Owner Officer V.P. & General Counsel				

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Each unit pertains to one share of the Issuer's common stock and may be settled either in cash or in stock based on date on which settlement occurs. Settlement will occur as the units vest, and to the extent such settlement occurs prior to the closing of the acquisition of

- (1) the Issuer by Novartis AG, the payment will be made in shares of the Issuer's common stock; otherwise, the units will be assumed by Novartis and payment will be made in cash based on the consideration paid per share of the Issuer's common stock in the Novartis acquisition.
- (2) One-for-One
- (3) Shares of the Issuer's common stock which become issuable upon the vesting of the units will be withheld by the Issuer in satisfaction of the applicable withholding taxes, unless the Reporting Person elects to pay such taxes in cash.

The units will vest in four equal, successive annual installments upon the Reporting Person's completion of each year of employment with the Issuer over the four-year period measured from the Grant Date. However, the units will vest in full on an accelerated basis upon an

(4) acquisition of the Issuer by a merger or asset sale in which the units are not assumed or upon the termination of the Reporting Person's employment with the Issuer under certain prescribed circumstances following certain changes in control or ownership of the Issuer (including the Novartis acquisition) in which the units are assumed.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.